AMPH · Amphastar Pharmaceuticals, Inc.
Market Cap
$936.26M
Shares
42.54M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$719.89M
-1.7%
FY2025
Net Income
$98.09M
-38.5%
FY2025
Gross Margin
49.46%
-1.6pp
FY2025
Operating Margin
19.5%
-8.6pp
FY2025
Diluted EPS
$2.03
-33.7%
FY2025
Operating Cash Flow
$156.12M
-26.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $730.02M | $719.89M | $731.97M | $644.4M | $498.99M | $437.77M | $349.85M | $322.36M | $294.67M | $240.18M | $255.17M | $251.52M | $210.46M | $229.68M | $204.32M | |
| $381.91M | $363.83M | $358.11M | $293.27M | $250.13M | $238.03M | $206.51M | $190.43M | $187.68M | $149.67M | $150.97M | $174.17M | $159.21M | $142.73M | $114.02M | |
| $348.11M | $356.06M | $373.86M | $351.12M | $248.86M | $199.74M | $143.34M | $131.92M | $106.99M | $90.51M | $104.2M | $77.35M | $51.26M | $86.96M | $90.3M | |
| — | 49.46% | 51.08% | 54.49% | 49.87% | 45.63% | 40.97% | 40.92% | 36.31% | 37.68% | 40.83% | 30.75% | 24.35% | 37.86% | 44.2% | |
| $94.57M | $85.84M | $73.91M | $73.74M | $74.77M | $60.93M | $67.23M | $68.85M | $57.56M | $43.5M | $41.52M | $37.27M | $28.87M | $33.02M | $31.16M | |
| $47.05M | $43.89M | $37.8M | $28.85M | $21.53M | $17.49M | $14.78M | $12.83M | $8.16M | $6.46M | $5.47M | $5.47M | $5.56M | $5.35M | $4.43M | |
| $92.21M | $85.93M | $56.72M | $51.54M | $45.06M | $51.43M | $50.38M | $50.28M | $49.89M | $44.46M | $41.83M | $41.5M | $34.81M | $30.97M | $27.22M | |
| $25.08M | $25.05M | $24.72M | $12.83M | $954K | $1.07M | $1.04M | $1.04M | $1.99M | $2.86M | $2.52M | $1.94M | $1.92M | $1.91M | $1.84M | |
| — | — | — | $25.74M | $12.6M | $10.23M | $9.03M | $7.06M | $6.05M | $6.42M | — | — | — | — | — | |
| $233.82M | $215.65M | $168.44M | $154.13M | $141.36M | $129.85M | $132.39M | $131.96M | $115.61M | $91.78M | $88.82M | $84.25M | $69.24M | $69.47M | $64.91M | |
| $114.29M | $140.4M | $205.42M | $196.99M | $107.5M | $69.89M | $10.95M | -$39K | -$8.62M | -$1.27M | $15.38M | -$6.9M | -$17.98M | $17.49M | $25.4M | |
| — | 19.5% | 28.06% | 30.57% | 21.54% | 15.96% | 3.13% | -0.01% | -2.93% | -0.53% | 6.03% | -2.74% | -8.54% | 7.61% | 12.43% | |
| — | — | — | $222.72M | $120.09M | $80.11M | $19.98M | $7.02M | -$2.57M | $5.15M | — | — | — | — | — | |
| $26.13M | $25.48M | $30.34M | $27.16M | $1.85M | $885K | $374K | $119K | $243K | $826K | $1.02M | $987K | $609K | $958K | $784K | |
| $9.36M | $8.68M | $10.61M | $5.46M | $1.32M | $601K | $642K | $997K | $456K | $425K | $270K | $315K | $243K | $187K | $242K | |
| -$12.26M | -$16.78M | -$15.66M | -$25.63M | $8.54M | $14.25M | -$6.32M | $60.27M | -$1.3M | $2.52M | -$746K | -$3.47M | -$165K | -$263K | $481K | |
| — | — | -$573K | -$1.98M | -$1.18M | -$208K | — | — | — | — | — | — | — | — | — | |
| $102.02M | $123.62M | $189.76M | $171.36M | $116.04M | $84.14M | $4.64M | $60.23M | -$9.93M | $1.25M | $14.63M | -$10.36M | -$18.15M | $17.23M | $25.88M | |
| $23.48M | $25.53M | $29.67M | $31.83M | $23.48M | $20.63M | $3.54M | $13.72M | -$3.27M | -$2.4M | $4.81M | -$7.58M | -$7.45M | $5.37M | $7.78M | |
| $78.55M | $98.09M | $159.52M | $137.55M | $91.39M | $62.12M | $1.4M | $48.94M | -$5.74M | $3.65M | $9.82M | -$2.79M | -$10.7M | $11.86M | $18.09M | |
| — | 13.63% | 21.79% | 21.34% | 18.31% | 14.19% | 0.4% | 15.18% | -1.95% | 1.52% | 3.85% | -1.11% | -5.08% | 5.16% | 8.86% | |
| — | — | — | — | — | $1.19M | -$306K | -$2.43M | -$922K | — | — | — | — | — | — | |
| $78M | $101.96M | $158.82M | $137.69M | $89.53M | $59.07M | $2.37M | $48.27M | -$7.65M | $6.24M | $7.6M | -$3.61M | -$12.35M | $11.86M | — | |
| USD/shares | $1.74 | $2.10 | $3.29 | $2.85 | $1.88 | $1.30 | $0.03 | $1.04 | -$0.12 | $0.08 | $0.22 | -$0.06 | -$0.25 | $0.31 | $0.47 |
| USD/shares | $1.69 | $2.03 | $3.06 | $2.60 | $1.74 | $1.25 | $0.03 | $0.98 | -$0.12 | $0.08 | $0.21 | -$0.06 | -$0.25 | $0.31 | $0.46 |
| shares | — | 46.74M | 48.43M | 48.27M | 48.55M | 47.78M | 47.04M | 46.98M | 46.4M | 46.11M | 45.38M | 44.96M | 41.96M | 38.71M | 38.58M |
| shares | — | 48.22M | 52.06M | 53M | 52.43M | 49.78M | 49.12M | 49.91M | 46.4M | 48.37M | 47.5M | 44.96M | 41.96M | 38.88M | 38.94M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2012–FY2025: $411.61M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.08×
EV/EBIT
—
Peer median 21.62×
P/E (TTM)
13.02×
Peer median 15.48×
Peer medians compare against the 46 similar-size Drug Manufacturers - Specialty & Generic companies (of 97 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Pharmaceutical Products Segment | $719,887,000 | $731,967,000 | $644,395,000 | $498,987,000 | — | — | — | — |
| Active Pharmaceutical Ingredient Segment | — | — | — | — | $18,198,000 | $18,478,000 | $20,357,000 | $23,607,000 |
| Finished Pharmaceutical Products Segment | — | — | — | — | $419,570,000 | $331,368,000 | $302,000,000 | $271,059,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $681,422,000 | $707,681,000 | $635,192,000 | $486,833,000 | $419,869,000 | $333,093,000 | $304,896,000 | $279,122,000 |
| France | $35,281,000 | $19,947,000 | $4,698,000 | $7,457,000 | $11,879,000 | $13,592,000 | $15,980,000 | $15,544,000 |
| China | $3,184,000 | $4,339,000 | $4,505,000 | $4,697,000 | $6,020,000 | $3,161,000 | $1,481,000 | — |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Product | $719,887,000 | $712,814,000 | $593,238,000 | $498,987,000 | $437,768,000 |
| Product And Service Other | — | $19,153,000 | $51,157,000 | — | — |
Key facts
CIK
1297184
CUSIP
03209R103
13F (30d)
169 filings
167 filers
Visit website
Investor relations